814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Richard T. Penson, David M. O’Malley, JW Kim, Stefan Zimmermann, Patricia Roxburgh, Joohyuk Sohn, Salomon M. Stemmer, Sara Bastian, Michelle Ferguson, Benoît You, Susan M. Domchek, Haiyan Gao, Helen K. Angell, Kassondra Meyer, Laura Opincar, Lone H. Ottesen, Daniel O. Koralek, Susana Banerjee